BTN3A1 and esophageal squamous cell carcinoma: Our findings provide a novel therapeutic target that can be used in combination with radiotherapy in ESCC patients, and this also suggests a possible scenario in which BTN3A1 upregulation could be a biomarker for selecting appropriate treatment regimens for ESCC patients.